Insmed (INSM) PT Raised to $237 at Barclays
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/5/2026
- S&P 500 futures steady after midterm rally; Nasdaq lags on chip weakness
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts INSM Hot Sheet
Price: $110.00 --0%
Rating Summary:
31 Buy, 2 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 16 | Down: 30 | New: 5
Rating Summary:
31 Buy, 2 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 16 | Down: 30 | New: 5
Join SI Premium – FREE
Barclays analyst Eliana Merle raised the price target on Insmed (NASDAQ: INSM) to $237.00 (from $231.00) while maintaining a Overweight rating.
You May Also Be Interested In
- Insmed (INSM) PT Lowered to $201 at Guggenheim
- MercadoLibre (MELI) PT Lowered to $2,300 at Scotiabank
- AppLovin Corp (APP) PT Lowered to $450 at Scotiabank
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
